EUVIMEDEUVIMED entdecken
Crossref

Strategic Design and Development of Indole‐Based Compounds as Potent Malic Enzyme 3 Inhibitors for Pancreatic Tumor Therapy

Gaurav Sheth, Shailesh R Shah iD, Prabal Sengupta, Tushar Jarag, Sabbirhusen Chimanwala, Kalapatapu V V M Sairam, Vaibhav Jain, Rashmi Talwar, Avinash Dhanave, Mehul Raviya, Harendra Jha, Rajasekhar Reddy Chilakala und 1 weitere

ChemMedChem · 2025

DOI: 10.1002/cmdc.202500470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Gaurav Sheth und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Sun Pharma Advanced Research Company Ltd., Vadodara, 391775, India. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Indoles, Antineoplastic Agents, Drug Design. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malic enzyme 3 (ME3) plays a critical role in the survival of SMAD4 −/− /ME2 −/− pancreatic ductal adenocarcinoma (PDAC) cells by supporting energy production and maintaining redox homeostasis. Therefore, targeting ME3 with small‐molecule inhibitors presents a promising therapeutic strategy for PDAC patients with SMAD4/ME2 deletions. Building upon our previously developed ME3 inhibitor, a systematic exploration of the structure–activity relationship (SAR) was undertaken to identify novel chemotypes. This effort led to the discovery of a new series of indole‐substituted piperazine carboxamides with potent ME3 inhibitory activity, among which compound 13 emerged to be the most effective in PDAC cell lines. Furthermore, the synergistic effects of the newly identified compound 13 with the mitogen‐activated protein kinase kinase (MEK) inhibitor trametinib were evaluated on Hs766T cells which revealed a significant synergism of this combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsIndolesAntineoplastic AgentsDrug DesignEnzyme InhibitorsHumansStructure-Activity RelationshipMolecular StructureDrug Screening Assays, AntitumorCell ProliferationCell Line, TumorDose-Response Relationship, DrugCarcinoma, Pancreatic Ductal

Stichwörter der Autor:innen

ME3 inhibitorsPDACanticancer agentscollateral lethalitymalic enzymes

Substanzen

IndolesAntineoplastic AgentsEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Sun Pharma Advanced Research Company Ltd., Vadodara, 391775, India.
  • Department of Chemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara, 390002, India.
  • Department of Chemical Sciences, School of Science, GSFC University, Vadodara, 391750, India.
  • Department of Bioinformatics and Computational Discovery, Sun Pharma Advanced Research Company Ltd., Vadodara, 391775, India.
  • Department of in vitro biology, Sun Pharma Advanced Research Company Ltd., Vadodara, 391775, India.
  • Faculty of Applied Sciences, Parul University, Vadodara, 391760, India.

ORCID-Profile: Shailesh R Shah, Trinadha Rao Chitturi

Zitieren

APA

Sheth, G., Shah, S. R., Sengupta, P., Jarag, T., Chimanwala, S., Sairam, K. V. V. M., Jain, V., Talwar, R., Dhanave, A., Raviya, M., Jha, H., Chilakala, R. R., & Chitturi, T. R. (2025). Strategic Design and Development of Indole‐Based Compounds as Potent Malic Enzyme 3 Inhibitors for Pancreatic Tumor Therapy. ChemMedChem. https://doi.org/10.1002/cmdc.202500470

Vancouver

Sheth G, Shah SR, Sengupta P, Jarag T, Chimanwala S, Sairam KVVM, et al. Strategic Design and Development of Indole‐Based Compounds as Potent Malic Enzyme 3 Inhibitors for Pancreatic Tumor Therapy. ChemMedChem. 2025. doi:10.1002/cmdc.202500470

BibTeX
@article{Sheth2025,
  author = {Sheth, Gaurav and Shah, Shailesh R and Sengupta, Prabal and Jarag, Tushar and Chimanwala, Sabbirhusen and Sairam, Kalapatapu V V M and Jain, Vaibhav and Talwar, Rashmi and Dhanave, Avinash and Raviya, Mehul and Jha, Harendra and Chilakala, Rajasekhar Reddy and Chitturi, Trinadha Rao},
  title = {Strategic Design and Development of Indole‐Based Compounds as Potent Malic Enzyme 3 Inhibitors for Pancreatic Tumor Therapy},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202500470}
}
Kostenlos starten →